{"id":"W4387135441","doi":"10.1136/ijgc-2023-esgo.45","title":"#1056 Mirvetuximab soravtansine demonstrates efficacy over investigator’s choice chemotherapy regardless of prior PARPi exposure in phase III MIRASOL trial","year":2023,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Internal medicine; Adverse effect; Confidence interval; Oncology; Progression-free survival; Clinical endpoint; Chemotherapy; Metastatic breast cancer; Topotecan; Clinical trial; Cancer; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001088431,0.0006313957,0.001522435,0.0002332112,0.000317085,0.001005129,0.0004675718,0.0008242386,0.009191765],"category_scores_gemma":[0.0009067933,0.0003729335,0.001469009,0.0002642638,0.0005366236,0.000866236,0.0002787162,0.003430261,0.001328856],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008844724,"about_ca_system_score_gemma":0.0008821885,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006690472,"about_ca_topic_score_gemma":0.003982603,"domain_scores_codex":[0.9996471,0.0001367224,0.0000274064,0.00007076374,0.00004150249,0.00007646016],"domain_scores_gemma":[0.9996244,0.00008317849,0.00008172463,0.00003664102,0.00002419695,0.0001498023],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5955974,0.01208636,0.005752611,0.002074425,0.005511554,0.0003050914,0.0003222328,0.004215929,0.03480431,0.002836839,0.02624914,0.310244],"study_design_scores_gemma":[0.6076269,0.31531,0.02196845,0.0002809243,0.0027205,0.0007823626,0.0001500676,0.003267884,0.008271221,0.001749481,0.03777364,0.00009856117],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9701816,0.007390986,0.0008414405,0.003944877,0.0008994434,0.0009725951,0.002741288,0.0004054803,0.01262231],"genre_scores_gemma":[0.9818332,0.003170838,0.001643124,0.002384099,0.0002818494,0.0005971933,0.002599421,0.00008021271,0.007410031],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009191765,"threshold_uncertainty_score":0.0307495,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06036787237546302,"score_gpt":0.4109277313982548,"score_spread":0.3505598590227917,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}